The companies working on more than half of the mental illness drugs under development are clustered in four U.S. states, according to research by the largest lobby for the drug industry.

The Pharmaceutical Research and Manufacturers of America compiled a study showing that of the 313 drugs, 192 are under development by companies in New York, New Jersey, North Carolina and California.

Read more